Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2022

View Archived Issues

rs41423247 SNP in NR3C1 gene predicts pneumonia complications in COVID-19

Novel vaccine candidates presented for Lassa fever

Merck & Co. patents orexin OX2 receptor agonists

Denali Therapeutics divulges new LRP3 inflammasome inhibitors

Dunad Therapeutics and collaborators present new GTPase KRAS inhibitors

Merck & Co. identifies new FXIa and/or KLKB1 inhibitors

U.S. researchers divulge new compounds for SARS-CoV-2 infection

Novel GLP-1 receptor agonist with improved oral bioavailability

Variants in the PABP-domain of PABPC1 associated with developmental delay

Genetic variants found in SLC35B2 gene tied to chondrodysplasia with hypomyelinating leukodystrophy

OliX subsidiary mCureX partners with Samyang and GC Pharma to advance mRNA vaccines

Vipergen enters derma drug discovery partnership with LEO Pharma

Lassen presents preclinical data on LASN-01 in preclinical models of skin fibrosis

Aqemia and Sanofi extend collaboration to use AI technology to optimize molecules to treat cancer

Nordic Bioscience and Roche strengthen biomarker collaboration

T cell-targeted vaccine for Coxiella burnetii infection shows promise in animal models

Blood vessel shape predicts what shape the heart is in

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...